Drug intelligence / Profile preview

DWC201903

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC201903 is a small molecule investigational drug developed by Daewoong Pharmaceutical. It has been evaluated in at least one completed Phase 1 clinical trial, which was a randomized, open-label, single-dose crossover study comparing its pharmacokinetics and safety to another compound (DWJ1421) in healthy male volunteers. The specific mechanism of action and therapeutic indication for DWC201903 have not been publicly disclosed. There are no known adverse events or FDA designations associated with this compound as of the latest available data[2][3][4].

Beyond the preview

Go deeper on DWC201903.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC201903.

Explore the full profile